Full Text CA-95-006


NIH GUIDE, Volume 24, Number 4, February 3, 1995

RFA:  CA-95-006

P.T. 34

  Urogenital System 
  Biomedical Research, Multidiscipl 
  Disease Prevention+ 

National Cancer Institute
National Institute of Environmental Health Sciences

Letter of Intent Receipt Date:  March 3, 1995
Application Receipt Date:  April 7, 1995


This Request for Application (RFA) is sponsored by the Cancer Centers
Branch of the Division of Cancer Biology, Diagnosis and Centers
(DCBDC) at the National Cancer Institute (NCI), and the Chemical
Exposures and Molecular Biology Branch, Division of Extramural
Research and Training (DERT), National Institute of Environmental
Health Sciences (NIEHS).  The co-sponsoring institutes invite grant
applications for development of new research programs in Prostate
Cancer.  The intent of this Request for Application (RFA) is to
promote through the use of the exploratory/developmental grant
mechanism (R21), development of interactive, multidisciplinary basic,
clinical, and prevention and control research base at the applicant
institution. Because basic research in prostate cancer has lagged
behind that of other solid tumors, emphasis on the plans for
developing basic research studies of prostate cancer is encouraged;
however, such studies should consider the opportunities for
interactive basic and clinical research and its potential for
translational research.

The major goal of this initiative is to promote development of
research focused on prostate cancer.  While basic laboratory research
should be the foundational component of the application, every
applicant is encouraged to consider including the elements that
address the special emphasis areas of environmental and occupational
carcinogenesis, prevention and control research opportunities, and/or
the unusually high incidence and mortality rates in underserved
minority or other high risk populations.  This initiative should
provide applicant institutions opportunities to significantly expand
the interactive, peer-reviewed, funded research base (e.g., R01s,
P01s) on prostate cancer.  Each institution should provide a
comprehensive plan for achieving this objective, which utilizes
innovative exploratory studies (i.e., pilot/feasibility studies) as a
basis for establishing long-term peer-reviewed funding, and new
recruitment, as a way of attracting critical scientific expertise.
This initiative should help the institution build a stable,
competitive research base that is interactive between the basic,
clinical, and prevention and control sciences, and that will position
the institution to have an impact on reducing the incidence and
mortality of prostate cancer through research.


The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA,
Development Grants for Research Programs in Prostate Cancer, is
related to the priority area of cancer.  Potential applicants may
obtain a copy of "Healthy People 2000" (Full Report:  Stock No.
017-001-00474-0 or Summary Report:  Stock No. 017-001-00473-1)
through the Superintendent of Documents, Government Printing Office,
Washington, DC 20402-9325 (telephone 202-783-3238).


All domestic non-profit and for-profit institutions are eligible to
apply for this initiative.  Foreign organizations and/or domestic
applications with international components are not eligible for this
initiative.  Because the intent of the RFA is to encourage
development of institution-wide, multidisciplinary, research programs
in prostate cancer, only one application per institution may be
submitted.  At those institutions that are NCI-designated Cancer
Centers, the prostate cancer program should become an integral
component of the cancer center and, as such, should benefit from the
spectrum of resources, the patient base of the center, as well as
participate in the interactive infrastructure of the center.  The
application must confirm this arrangement by including a statement
co-signed by the Principal Investigator of the proposed R21 grant and
the Center Director.  Institutions with P20 Feasibility Specialized
Programs of Research Excellence (SPORE) grants in prostate cancer are
eligible to apply.  However, institutions that already have prostate
cancer research programs supported by the P30 Cancer Center Support
Grants (CCSG) and/or P50 SPOREs in prostate cancer research can apply
only for the purpose of expanding their research base in
environmental carcinogenesis and occupational carcinogenesis, and in
minority, and other underserved, high risk special populations where
prostate cancer incidence and mortality are disproportionately higher
in their regions of influence.


This RFA will use the National Institutes of Health (NIH)
exploratory/developmental grant (R21) mechanism.  Responsibility for
the planning, direction, and execution of the proposed project will
be solely that of the applicant.  The total project period for an
application submitted in response to this RFA may not exceed four
years.  The anticipated award date is September 1, 1995.  Because the
nature and scope of the proposed developing program may vary, it is
anticipated that the size of an award will vary also.  This RFA is a
one-time solicitation.


The NCI anticipates setting aside approximately $1.5 million in total
costs in FY 1995 to fund the applications submitted in response to
this RFA.  The budget request is limited to $300,000 total costs per
year, and the total award period will be for no more than four years.
The NCI anticipates funding at least five applications.  This funding
level is dependent on the receipt of a sufficient number of
applications of high scientific merit. Although this program is
provided for in the financial plans of the NCI, the award of grants
pursuant to this RFA is contingent upon availability of funds for
this purpose.  No funds are obligated by the NIEHS at this time.
However, based on funds that may be available at a later date, the
NIEHS may co-fund several applications with the NCI.


Background and Scope

Prostate cancer, now the most common cancer in United States males,
is the second leading cause of cancer deaths in men.  At present,
this disease results in more than 38,000 deaths annually. African-
American males have the highest prostate cancer incidence in the
world, with two-fold higher mortality rates than in white males.  The
reasons for this racial difference are unclear, although
environmental, dietary, and hormonal factors are under study.  A
recent analysis of mortality data comparing deaths due to prostate
cancer in African-American farming populations from three
southeastern states compared to 21 northeast and north central states
indicated 38 percent higher incidence of prostate cancer deaths in
the African-American farmers in the southeast relative to those in
the other 21 states examined (JNCI, 86:1718-1719, 1994).  This study
supports the notion of association of prostate cancer risk and
certain occupations, and the need for multidisciplinary efforts in
prostate cancer research focused on environmental and occupational
risk factors.

The economic burden of prostate cancer in terms of direct medical
expenses alone, including a quarter of a million hospitalizations, is
estimated to cost upwards of $1.5 billion annually.  Prostate cancer
research has lagged far behind research in other major forms of
cancer, and there has been a lack of new investigators entering the
field.  In part, this has been due to lack of suitable in vitro and
in vivo model systems and lack of accessibility to human prostate
tissues.  Effective reduction of incidence and mortality due to
prostate cancer will require a concerted effort to expand the
opportunities and the scientific information base.

The prostate cancer problem offers challenging opportunities in both
basic and clinical scientific research.  It has also attracted public
attention as a major disease threat directly affecting the lives of
thousands of men.  It is expected that in developing a new research
program in prostate cancer, innovative pilot projects and recruitment
of new investigators to be supported by this initiative will
emphasize a mix of interactive basic, clinical, and prevention and
control research, placing special emphasis on issues of environmental
and occupational carcinogenesis, and of unusually high incidence and
mortality in minority and other underserved high risk populations.

The special feature of this initiative is to develop a highly
interactive research program in prostate cancer by providing
opportunities for bringing together investigators with mutual and
complementary interests to engage in prostate cancer research, new
recruitment, and for pilot/feasibility studies focused on the
prostate cancer problem that will lead to establishment of an
interactive, multidisciplinary research base in prostate cancer at
the applicant institution.


The purpose of this RFA is to promote development of a new, broad,
interactive research base (e.g., R01s, P01s) at the applicant
institutions for the conduct of multidisciplinary research in
prostate cancer, placing special emphasis on issues of environmental
and occupational carcinogenesis, and prevention and control research.
The ultimate objective is to reduce incidence and mortality, and to
increase and improve survival to the disease.  An important aspect of
this initiative is to examine the extent and impact that
environmental and occupational exposures contribute to prostate
cancer incidence and mortality among minority and other underserved
populations, and to develop effective means of cancer prevention and
control in these special populations.

The application must demonstrate commitment and potential for
establishing a new research program in prostate cancer, which when
fully developed, should have a substantial, interactive,
multidisciplinary peer-reviewed funded research base of basic science
and clinical research, and prevention and control research
investigators engaged in prostate cancer research.  Likewise, the P30
CCSG and/or P50 SPORE grantees, must demonstrate the potential of
expanding the research base of their existing prostate cancer program
into the special emphasis areas and the resultant impact on the
incidence and morbidity of the disease.

The exploratory developmental grant mechanism provides funds in areas
that can be used flexibly for development of new multidisciplinary
research program as follows:  (a) planning activities, (b) pilot
projects, and (c) recruitment of new investigators.  The application
should provide a detailed plan by which the requested funds in these
areas will be used in a balanced way over the proposed grant period
to achieve the objectives.

Each application must include the following elements listed below.
Additional considerations are noted at the end of this section for
those institutions with existing prostate cancer programs supported
by the P30 CCSG and/or P50 SPORE mechanisms.

1.  Institutional commitment:  The institution should delineate
special commitments that go beyond those associated with regular
research grant applications (e.g., R01s), that demonstrate how this
program will be given a high priority development, and that will
improve chances for success if an award is made.  These special
commitments may be in the form of commitments to recruit new
scientific talent, administrative resources, provision of
discretionary resources to the program, assignment of contiguous
research space, cost-sharing of centralized resources, or other ways
to be proposed by the applicant.

2.  Qualified Principal Investigator/Program Director:  A leader
should be selected as Principal Investigator/Program Director who can
oversee and conduct planning activities, provide direction to the
developing program and ensure a multidisciplinary research emphasis.
Describe the scientific qualifications and administrative competence
of the proposed individual for directing the planning and development
effort.  This individual must devote a significant proportion of
his/her time to this endeavor.

3.  Planning and evaluation process:  The application should describe
a planning and evaluation process for the developing program.  For
example, it could include an internal planning committee composed of
senior leaders of the institution that will assist the Principal
Investigator in developing the program.  Where special input may be
necessary, highly regarded specialists in prostate cancer research
may be used as external advisors on an ad hoc basis.  The application
should address the process for prioritizing and distributing
resources among (a) pilot/feasibility studies, (b) recruitment of new
investigators, and (c) retreats and meetings.

4.  Plan:  The application must provide a plan for developing a
program with sufficient scientific breadth and depth, that is
cohesive, multidisciplinary, and takes maximum advantage of the
institution's resources and research capabilities.  The planned
program would be expected to identify a nucleus of investigators
knowledgeable of and involved in prostate cancer research, and to
identify and bring together new investigators in and outside the
institution who wish and can contribute to the development of basic,
clinical, and prevention and control research in prostate cancer, and
in the special emphasis areas, where applicable.  The application
should describe how this existing research base will coalesce within
the plans of a new developing program.

This initiative includes recruiting new investigators and supporting
pilot projects/feasibility studies.  The proposed plan should fully
describe how this new recruitment and support of pilot studies would
enhance the expertise, strengthen and/or broaden the research base of
the program, and enhance the special emphasis areas, thereby creating
a more productive, interactive research environment.

5.  Exploratory pilot studies:  The most significant portion of the
budget should focus on initiating novel pilot projects or feasibility
studies that will stimulate basic, clinical, and prevention and
control research in prostate cancer.  It is expected this would help
build the peer-reviewed, funded research base in support of prostate
cancer, and at the same time enhance the research capabilities of the
institution in special emphasis areas.  It is also expected that
interactive pilot studies will have the potential to facilitate
translational research.

The application should include a plan and rationale for selecting the
emphasis areas for pilot projects/feasibility studies.  Pilot
projects or feasibility studies may be collaborative among
scientists.  It is important that the funds requested in this
category are for pilot/feasibility studies that take maximum
advantage of new research opportunities.  The application should
include the process for selecting pilot studies for funding that
represent the most innovative ideas, are likely to have the greatest
impact on reducing prostate cancer incidence and mortality, and are
most likely to result in expanding the funded research base of the
program.  A proposed list of pilot projects/feasibility studies
should be presented highlighting those that would be selected for
initial funding.  For the projects selected for initial funding, a
scientific plan in sufficient detail for peer-review should be
included in the body of the application.  The scientific plan must
not exceed three pages, and should include short introduction,
hypothesis, experimental approach, expected results, and its
significance to prostate cancer.  The expectation is that successful
pilot studies will become fully developed projects within the
program, and be submitted as research projects for competitive
support (e.g., R01s, P01s).  New innovative pilot studies may be
initiated during the award period if approved by the institutional
selection and planning process.  However, the NCI staff should be
informed of such additions and/or changes.  Abstracts of pilot
studies to be selected by the institutional selection process for
funding in subsequent years of the award period should not exceed one
page, and, for each pilot study, should include the hypothesis,
specific aims, methods of approach, and significance to prostate
cancer.  These should be appended to the application.

6.  Recruitment of new investigators:  A strong expectation is that
the proposed plan will identify the expertise of some new
investigators who will be recruited to the institution and strengthen
and/or broaden the research base of the program by enhancing special
emphasis areas and/or creating a more productive, interactive
research environment.

7.  A substantial prostate cancer patient population:  When fully
developed, each program should be recognized as a substantive
interactive program in innovative basic and clinical research, and
prevention and control research, with a high degree of opportunity
for moving basic research findings into the patient and population
research settings.  The application must demonstrate and document
access to a patient population that can benefit from the
opportunities provided by this initiative.

Additional considerations for special emphasis applications from
institutions with existing prostate cancer programs funded by the P30
CCSG and/or P50 SPORE mechanisms will be:

o Principal Investigator/Program Director:  It is expected that the
Program Director of the existing prostate cancer program will be the
Principal Investigator/Program Director of this developing program.

o  Description of the existing prostate cancer research program and
explanation as to how it will complement and enhance new research
efforts in the special emphasis areas, i.e, environmental and
occupational carcinogenesis, and of unusually high incidence and
mortality in minority and other underserved high risk populations.

o  All elements (e.g., exploratory pilot studies, recruitment, etc.)
of the application should focus on strengthening the special emphasis
areas described above.


It is the policy of the NIH that women and members of minority groups
and their subpopulations must be included in all NIH supported
biomedical and behavioral research projects involving human subjects,
unless a clear and compelling rationale and justification is provided
that inclusion is inappropriate with respect to the health of the
subjects or the purpose of research.  This new policy results from
the  NIH Revitalization Act of 1993 (Section 492B of Public Law
103-43) and supersedes and strengthens the previous policies
(Concerning the Inclusion of Women in Study Populations, and
Concerning the Inclusion of Minorities in Study Populations) which
have been in effect since 1990.  The new policy contains some new
provisions that are substantially different from the 1990 policies.

All investigators proposing research involving human subjects should
read the "NIH Guidelines on the Inclusion of Women and Minorities as
Subjects in Clinical Research", which have been published in the
Federal Register of March 28, 1994 (FR 59 14508-14513) and reprinted
in the NIH Guide for Grants and Contracts, Volume 23, Number 11,
March 18, 1994.

Investigators may obtain copies from these sources or from the
program staff listed under INQUIRIES.  Program staff may also provide
additional relevant information concerning the policy.


Prospective applicants are asked to submit, by March 3, 1995, a
letter of intent that includes a descriptive title of the proposed
application, the name, address, and telephone number of the Principal
Investigator, the identities of other key personnel and participating
institutions, and the number and title of the RFA in response to
which the application may be submitted.

Although a letter of intent is not required, is not binding, and does
not enter into the review of a subsequent application, the
information it contains allows the NCI staff to estimate the
potential review workload and avoid conflict of interest in review.
It will also allow the NCI program staff to contact potential
applicants and provide them with the earliest opportunity possible to
obtain clarifications of the initiative and to prepare the most
competitive application possible that meets all of the requirements
of the initiative.

The letter of intent is to be sent to Dr. Jaswant S. Bhorjee at the
address listed under INQUIRIES.


The research grant application form PHS 398 (rev. 9/91) is to be used
in applying for these grants.  These forms are available at most
institutional offices of sponsored research; from the Office of
Grants Information, Division of Research Grants, National Institutes
of Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892,
telephone 301-710-0267; and from the program administrator listed

Although form PHS 398 was developed for investigator-initiated
research applications, the instructions in the PHS 398 application
kit must be followed where appropriate.  Applications must meet all
eligibility requirements as described above and must address all
programmatic requirements (see SPECIAL REQUIREMENTS above) in the
RFA.  In preparing the written application, the applicant should also
examine the review criteria provided under the REVIEW CONSIDERATIONS

The application must contain the following elements and supporting
documents noted below:

1.  Plan for the development of the program should be presented in
the Research Plan section of the PHS 398 application.  This section
should address the elements noted under SPECIAL REQUIREMENTS above,
and should not exceed 40 pages.

2.  Overall and Individual Budgets and Justifications:  An individual
budget should be submitted for individual areas of 'Principal
Investigator/Program Director', 'pilot studies', 'recruitment of new
investigators', and 'planning and evaluation'.  The R21 Developmental
Grant will support the following budgetary items:

o  Partial salary of the Principal Investigator/Program Director.

o  Funds for pilot studies in support of technical assistance and/or
conduct of research.

o  Partial funds for recruitment of new investigators.  The intent is
to co-share support with the institution for costs of salary and
recruitment package so that more recruitment opportunities may be

o  Planning and evaluation funds to support the travel and per diem
costs of outside advisors or consultants during the initial phases of
planning.  Also minimal funds for special retreats and meetings for
the purpose of prostate cancer program development.

3.  Biographical sketches of all key personnel and outside
consultants (use PHS 398 format).  The publications listed as part of
the biographical sketches should highlight those that are relevant to
prostate cancer research.

4.  Supporting Documents:

o  Research Grants and Contracts.  Provide a list of all active
funded cancer and cancer related research grants and contracts that
may constitute the initial research base of the proposed program.
The projects should be listed in alphabetical order by PI name, and
should be presented in a table format to include PI name, funding
agency (if NIH, identify sponsoring institute, i.e., CA, AG, ES),
I.D. number, project title, grant award period, total direct costs,
and current annual direct costs.

o  Letters or documents from senior officials of the institution
documenting institutional support for the proposed planning and
development process.  Co-signed letter by the Principal Investigator
and the Cancer Center Director of the institution in an NCI-
designated Cancer Center supported by a P30 CCSG.

The RFA label available in the application form PHS 398 (rev. 9/91)
must be affixed to the bottom of the face page of the application.
Failure to use this label could result in delayed processing of the
application such that it may not reach the review committee in time
for review.  In addition, the RFA title and number must be typed on
line 2a of the face page of the application form and the YES box must
be marked.

Submit a signed, typewritten original of the application, including
the Checklist, and three signed, photocopies, in one package to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**

At the time of submission, two additional copies of the application
must be sent to:

Ms. Toby Friedberg
Division of Extramural Activities
National Cancer Institute
Executive Plaza North, Room 636
6130 Executive Boulevard
Bethesda, MD  20892-7405 (if using U.S. Postal service) Rockville, MD
20852 (if express mail or carrier service)

Applications must be received by April 7, 1995.  Applications
received after this date will not be accepted.  Also, the Division of
Research Grants (DRG) will not accept any application in response to
this RFA any part of which is the same as one currently being
considered by any other review group or NIH awarding unit.


Review Procedures

Upon receipt, applications will be reviewed initially for
completeness by DRG and responsiveness by the NCI.  Incomplete
applications that have not addressed all of the required elements
noted under SPECIAL REQUIREMENTS or that do not meet the eligibility
requirements as noted above, will be returned to the applicant
without further consideration.  Evaluation for responsiveness to the
program requirements stated in the RFA is an NCI program staff
function; this will be done stringently and will be based primarily
on the clear orientation of the application to human prostate cancer.
Applications judged to be non-responsive to this RFA will be returned
without review.

Applications that are complete and responsive to this RFA will be
evaluated for scientific and technical merit and for special
requirements of the RFA by an appropriate peer-review group convened
by the NCI in accordance with the review criteria stated below.  The
second level of review will be performed by the National Cancer
Advisory Board and/or National Advisory Environmental Health Services

Review Criteria

The major factors to be considered in the evaluation of all
applications are given below.  Additional factors are noted in a
separate section for applications from institutions with existing P50
SPOREs in prostate cancer and/or with an established prostate cancer
research program as part of a P30 Cancer Center Support Grant.

1.  The Institutional Commitment

o  adequacy of space and other normal institutional resources to
promote development of the proposed prostate cancer research program;

o  strength of the special commitments of the institution, which will
enhance the successful development of a prostate cancer research
program (e.g., commitments to positions, discretionary resources for
the Principal Investigator, specialized space).

2.  Overall Program Organization and Capability

o  the scientific qualifications and demonstrated leadership
capabilities of the proposed Principal Investigator/Program Director;
adequacy of the time commitment of the Principal Investigator/Program
Director for the demands of a developing program;

o  the potential effectiveness of planning and evaluation process,
including internal advisory groups and consultants; adequacy and
qualifications of proposed advisory membership; adequacy and
effectiveness of the decision making process, particularly with
respect to planning the program research directions, enhancing
interactive and collaborative efforts, and allocating funds for new
recruitment and pilot studies, including the special emphasis areas,
where appropriate;

o  adequacy of the proposed development plan, including development
of a cohesive, focused research theme, consideration of special
emphasis areas, where appropriate, and vision for the future of the
program; adequacy of prostate cancer or related ongoing research
activities (e.g., funded research projects) as a foundation upon
which to build a substantial multidisciplinary research program in
prostate cancer;

o  overall general adequacy of the proposed pilot
projects/feasibility studies in terms of their innovativeness and
likelihood of advancing the knowledge base in prostate cancer,
improving overall research capability, stimulating interactive
research between basic science and clinical research investigators,
prevention and control research, and their potential for facilitating
translational research; adequacy and potential of the pilot studies
in building the peer-reviewed funded research base of the prostate
cancer program (specific evaluation of pilot studies for merit is in
the next section);

o  adequacy of plans and priorities for recruitment of new
investigators for the specific purpose of creating a broad,
interactive and interdisciplinary program, and/or for enhancing
special emphasis areas;

o  adequacy of access to patients and to a population for conducting
of potential new therapeutic, prevention and control research; at
institutions where immediate access to patient populations is not
available, adequacy of plans to access patient populations for
clinical research and/or collaborations with clinical investigators;

o  the adequacy of the procedures, processes, and plans for promoting

o  Adequacy of plans to include minorities and their subgroups as
appropriate for the scientific goals of the research.  Plans for the
recruitment and retention of subgroups will also be evaluated.

3.  Individual Pilot Projects/Feasibility Studies

o  scientific merit of the proposed pilot/feasibility study;

o  qualifications and demonstrated competence of the investigators to
conduct the proposed research; adequacy of all key laboratory and
clinical personnel associated with the pilot project;

o  degree to which the proposed pilot project addresses an issue of
substantive importance for enhancing knowledge base in human prostate

o  originality, novelty, and innovativeness of the proposed pilot
project and its relevance to the overall goals and objectives of the

o  potential of the degree to which the proposed pilot project/study
is likely to promote basic/clinical interactions and will be
interactive with other pilot studies in the program.

The above criteria apply to all competing applications, including the
special emphasis applications.  Additionally, the special emphasis
applications will be evaluated for how well the existing prostate
cancer research program complements and enhances new research efforts
in the special emphasis areas, i.e., environmental and occupational
carcinogenesis, and of unusually high incidence and mortality in
minority and other underserved high risk populations.

The reviewers will be asked to recommend a period of time for support
(not to exceed four years) and budget for each year approved not to
exceed the dollar limit set forth in the RFA.


The earliest anticipated date of award is September 1, 1995.  The
following will be considered in making funding decisions:  (a)
priority score, (b) availability of funds, and (c) programmatic


Inquiries concerning this RFA are encouraged.  The opportunity to
clarify any issues or questions from potential applicants is welcome.

Direct inquiries regarding programmatic issues to:

Jaswant S. Bhorjee, Ph.D.
Division of Cancer Biology, Diagnosis, and Centers
National Cancer Institute
Executive Plaza North, Room 502
6130 Executive Boulevard MSC 7386
Bethesda, MD  20892-7386
Telephone:  (301) 496-8531
FAX:  (301) 402-0181
Email:  bhorjeej@dcbdcep.nci.nih.gov

Gwen W. Collman, Ph.D.
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
P.O. Box 12233
Research Triangle Park, NC  27709
Telephone:  (919) 541-4980
FAX:  (919) 541-2843

Direct inquiries regarding fiscal matters to:

Carolyn Mason
Grants Administration Branch
National Cancer Institute
Executive Plaza South, Room 243
6120 Executive Boulevard MSC 7150
Bethesda, MD  20892-7150
Telephone:  (301) 496-7800 ext. 259

Dorothy Williams
Grants Management Specialist
National Institute of Environmental Health Sciences
Building 2, Mail Drop 2-01
P.O. Box 12233
Research Triangle Park,  NC 27709
Telephone:  (919) 541-2749


This program is described in the catalog of Federal Domestic
Assistance Number 93.397.  Awards are made under authorization of the
Public Health Service Act, Title IV, Part A (Public Law 78-410, as
amended by Public Law 99-158, 42 USC 241 and 285) and administered
under PHS grants policies and Federal Regulations 42 CFR Part 52 and
45 CFR Part 74.  This program is not subject to the intergovernmental
review requirements of Executive Order 12372 or Health Systems Agency

The PHS strongly encourages all grant recipients to provide a smoke-
free workplace and promote the non-use of all tobacco products.  This
is consistent with the PHS mission to protect and advance the
physical and mental health of the American people.


Return to RFAs Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.